{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:49:03Z","timestamp":1758635343878,"version":"3.37.3"},"reference-count":39,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Obinutuzumab (G) chemoimmunotherapy demonstrated improved progression-free survival (PFS) vs rituximab-based chemoimmunotherapy in patients with previously untreated follicular lymphoma (FL) in the GALLIUM trial. Atezolizumab (atezo) is a programmed death-ligand 1 inhibitor with a complementary mechanism of action to G\u00a0by\u00a0restoring cytotoxic T-cell function. We evaluated the safety and efficacy of atezo-G-bendamustine in patients with previously untreated FL in a phase Ib\/II trial (#NCT02596971). A safety run-in phase was followed by an expansion phase with atezo-G-bendamustine induction and atezo-G maintenance for \u226424 months. Forty patients\u00a0with previously untreated FL were enrolled and treated with atezo-G-bendamustine. The primary endpoint, complete response (CR) rate, assessed by an independent review committee (IRC; modified Lugano 2014 criteria) was 75.0% (95% confidence interval [CI], 61.3% to 85.8%). Three-year investigator-assessed PFS and overall survival rates were 80.9% (95% CI, 63.9% to 90.5%) and 89.3% (95% CI, 73.9% to 95.9%), respectively. At baseline, 21\/40 patients had circulating lymphoma-specific clonotypes and\u00a0underwent repeat testing at end of induction; all were minimal residual disease negative (10\u22125 sensitivity), with 16 (76.2%) CRs, 3 (14.3%) partial responses, and 2 (9.5%) with stable disease (IRC assessed). Grade 5 (fatal) adverse events (AEs) were reported in 5\u00a0patients. The efficacy of atezo-G-bendamustine in previously untreated FL did not appear\u00a0superior to G-bendamustine efficacy as seen in the GALLIUM trial, and the addition of atezo to G-bendamustine was associated with an increased risk of AEs. Particularly due to\u00a0the unfavorable safety profile, this regimen cannot be recommended in patients with previously untreated FL. This trial was registered at www.clinicaltrials.gov as #NCT02596971.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006131","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T01:17:18Z","timestamp":1648775838000},"page":"5659-5667","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma"],"prefix":"10.1182","volume":"6","author":[{"given":"Anas","family":"Younes","sequence":"first","affiliation":[{"name":"1Memorial Sloan-Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5144-6710","authenticated-orcid":false,"given":"John M.","family":"Burke","sequence":"additional","affiliation":[{"name":"2US Oncology Research, The Woodlands, TX"},{"name":"3Rocky Mountain Cancer Center, Aurora, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1116-3246","authenticated-orcid":false,"given":"Catherine","family":"Diefenbach","sequence":"additional","affiliation":[{"name":"4Perlmutter Cancer Center of NYU Langone Health, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Ferrari","sequence":"additional","affiliation":[{"name":"5Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrus","family":"Khan","sequence":"additional","affiliation":[{"name":"6Allegheny Health Network Cancer Institute, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[{"name":"2US Oncology Research, The Woodlands, TX"},{"name":"7Willamette Valley Cancer Institute, Eugene, OR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[{"name":"8Ospedale Santa Maria delle Croci, Ravenna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitra","family":"Ujjani","sequence":"additional","affiliation":[{"name":"9Seattle Cancer Care Alliance\/Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-2747","authenticated-orcid":false,"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[{"name":"10Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Yuen","sequence":"additional","affiliation":[{"name":"11Calvary Mater Newcastle Hospital, Newcastle, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aparna","family":"Raval","sequence":"additional","affiliation":[{"name":"12Genentech, Inc., South San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh","family":"Shivhare","sequence":"additional","affiliation":[{"name":"13Roche Products, Welwyn Garden City, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina G.","family":"Nielsen","sequence":"additional","affiliation":[{"name":"14F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gila","family":"Sellam","sequence":"additional","affiliation":[{"name":"14F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gilbertson","sequence":"additional","affiliation":[{"name":"15School of Clinical Sciences, Monash Health, Monash University, Melbourne, VIC, Australia"},{"name":"16Department of Haematology, Monash Health, Monash University, Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"issue":"2","key":"2023053013335013200_bib1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajh.24937","article-title":"Follicular lymphoma: 2018 update on diagnosis and management","volume":"93","author":"Freedman","year":"2018","journal-title":"Am J Hematol"},{"key":"2023053013335013200_bib2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab: the world\u2019s first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front Oncol"},{"issue":"3","key":"2023053013335013200_bib3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"ESMO Guidelines Committee. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"2023053013335013200_bib4","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"28","key":"2023053013335013200_bib5","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"2023053013335013200_bib6","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.19.01073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","volume":"37","author":"Bachy","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2023053013335013200_bib7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2023053013335013200_bib8","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"2023053013335013200_bib9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1182\/blood.V128.22.613.613","article-title":"Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study","volume":"128","author":"Pott","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2023053013335013200_bib10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/17474086.2017.1291339","article-title":"When to treat patients with relapsed follicular lymphoma","volume":"10","author":"Cheah","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"2023053013335013200_bib11","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s40265-016-0618-8","article-title":"Atezolizumab: First Global Approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"issue":"8","key":"2023053013335013200_bib12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-04-421826","article-title":"High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells","volume":"121","author":"Myklebust","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2023053013335013200_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"24","key":"2023053013335013200_bib14","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-12-1362","article-title":"Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1","volume":"18","author":"Chen","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"7528","key":"2023053013335013200_bib15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"17","key":"2023053013335013200_bib16","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1073\/pnas.1016569108","article-title":"Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy","volume":"108","author":"Stagg","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2023053013335013200_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-019-0730-9","article-title":"Combination regimens with PD-1\/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies","volume":"12","author":"Wang","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2023053013335013200_bib18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/annonc\/mdx686","article-title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","volume":"29","author":"Rotte","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"2023053013335013200_bib19","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2023053013335013200_bib20","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023053013335013200_bib21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2023053013335013200_bib22","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2023053013335013200_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12920-016-0220-7","article-title":"Immunoseq: the identification of functionally relevant variants through targeted capture and sequencing of active regulatory regions in human immune cells","volume":"9","author":"Morin","year":"2016","journal-title":"BMC Med Genomics"},{"issue":"9873","key":"2023053013335013200_bib24","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"2023053013335013200_bib25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2016.152272","article-title":"Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma","volume":"102","author":"Grigg","year":"2017","journal-title":"Haematologica"},{"key":"2023053013335013200_bib26","unstructured":"Genentech Inc\n          . Highlights of prescribing information. Tecentriq (atezolizumab) injection, for intravenous use. Accessed 15 June 2021. https:\/\/www.gene.com\/download\/pdf\/tecentriq_prescribing.pdf."},{"key":"2023053013335013200_bib27","unstructured":"Roche\n          . Tecentriq summary of product characteristics. Accessed 31 August 2021. https:\/\/www.medicines.org.uk\/emc\/product\/8442\/smpc."},{"key":"2023053013335013200_bib28","unstructured":"Genentech, Inc\n          . Tecentriq atezolizumab: connect with purpose. Accessed 12 October 2021. https:\/\/www.tecentriq-hcp.com\/."},{"key":"2023053013335013200_bib29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2147\/DDDT.S188893","article-title":"Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis","volume":"13","author":"Tie","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"s2","key":"2023053013335013200_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/hon.2437_126","article-title":"A\u00a0phase Ib study evaluating the safety and clinical activity of atezolizumab combined with obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphoma (NHL)","volume":"35","author":"Palomba","year":"2017","journal-title":"Hematol Oncol"},{"issue":"19","key":"2023053013335013200_bib31","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1158\/1078-0432.CCR-20-0558","article-title":"TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti\u2013PD-1 response in follicular lymphoma","volume":"26","author":"Yang","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2023053013335013200_bib32","doi-asserted-by":"crossref","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"3","key":"2023053013335013200_bib33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3109\/10428194.2015.1110748","article-title":"Bendamustine associated immune suppression and infections during therapy of hematological malignancies","volume":"57","author":"Gafter-Gvili","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"10030","key":"2023053013335013200_bib34","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"2023053013335013200_bib35","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"issue":"34","key":"2023053013335013200_bib36","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1200\/JCO.2006.06.4766","article-title":"Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients","volume":"24","author":"Alvaro","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 13","key":"2023053013335013200_bib37","doi-asserted-by":"crossref","first-page":"S1516","DOI":"10.21037\/jtd.2017.12.52","article-title":"Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients","volume":"10","author":"Remon","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"issue":"5","key":"2023053013335013200_bib38","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"2023053013335013200_bib39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cllc.2020.05.008","article-title":"Clinical activity and safety of atezolizumab in a phase 1 study of patients with relapsed\/refractory small-cell lung cancer","volume":"21","author":"Chiang","year":"2020","journal-title":"Clin Lung Cancer"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/20\/5659\/2054052\/blooda_adv-2021-006131-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/20\/5659\/2054052\/blooda_adv-2021-006131-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T13:34:37Z","timestamp":1685453677000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/20\/5659\/484508\/Safety-and-efficacy-of-atezolizumab-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":39,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2022,10,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006131","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2022,10,19]]}}}